Order-Made Medical Research Inc.

Santen Pharmaceutical Co., Ltd.

Hirotada Akiyama

Yasufumi Murakami

Shigeki Mukoubata

Hiroyuki Satofuka

Koji Konomi

Tatsuji Kurose

Sae Akao

Masaya Ohtsu

Yoko Okabe

Kensuke Ohse

Shigeki Mukobata

An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10mol/L or less.

High-affinity anti-VEGF antibody KLHa505

An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.

Antibody inhibiting binding of VEGF to NRP1

An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1&#xd7;10mol/L or less.

High-affinity anti-VEGF antibody

The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.

Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody

Growing community of inventors

Chiba, Japan

Hirotada Akiyama